Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

International scoring system for evaluating prognosis in myelodysplastic syndromes

Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · see citing works

Proposals for the classification of the myelodysplastic syndromes

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619 · see citing works

WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)

(2015) · doi:10.1002/9781118853771.ch51 · Cited by 3,290 · see citing works

World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Müller‐Hermelink, H. K., Vardiman, J. W., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,261 · see citing works

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686 · see citing works

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · see citing works

The World Health Organization (WHO) classification of the myeloid neoplasms

Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,191 · see citing works

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137 · see citing works

Age and acute myeloid leukemia

Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,352 · see citing works

Acute Myeloid Leukemia

Löwenberg, B., Downing, J. R., & Burnett, A. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,283 · see citing works

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619 · see citing works

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608 · see citing works

Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

Silverman, L. R., McKenzie, D. R., Peterson, B. L., Holland, J. F., Backstrom, J. T., Beach, C. L., & Larson, R. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4346 · Cited by 550 · see citing works

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

Bowen, D., Culligan, D. J., Jowitt, S. N., Kelsey, S. M., Mufti, G. J., Oscier, D. G., Parker, J., & of the UK MDS Guidelines Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.03907.x · Cited by 300 · see citing works

Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

Germing, U., Gattermann, N., Strupp, C., Aivado, M. A., & Aul, C. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00088-6 · Cited by 296 · see citing works

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

Rowe, J. M., Neuberg, D. S., Friedenberg, W. R., Bennett, J. M., Paietta, E. M., Makary, A. Z., Liesveld, J. L., Abboud, C. N., Dewald, G. W., Hayes, F. A., et al. (2003) · Blood · doi:10.1182/blood-2003-05-1686 · Cited by 277 · see citing works

The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly

Menzin, J., Lang, K., Earle, C. C., Kerney, D. L., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276 · see citing works

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.

Tilly, H., Castaigné, S., Bordessoule, D., Casassus, P., Prisé, P. Y. L., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259 · see citing works

Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

Estey, E. H., Thall, P. F., Beran, M., Kantarjian, H. M., Pierce, S. A., & Keating, M. J. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229 · see citing works

Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.

Löwenberg, B., Suciu, S., Archimbaud, E., Ossenkoppele, G. J., Verhoef, G. E. G., Vellenga, E., Wijermans, P., Berneman, Z. N., Dekker, A. W., Stryckmans, P. A., et al. (1997) · PubMed · doi:10.1182/blood.v90.8.2952 · Cited by 205 · see citing works

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

Faderl, S. H., Ravandi, F., Huang, X., Garcia‐Manero, G., Ferrajoli, A., Estrov, Z. E., Borthakur, G. M., Verstovšek, S., Thomas, D. A., Kwari, M. I., et al. (2008) · Blood · doi:10.1182/blood-2007-11-124602 · Cited by 199 · see citing works

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

Anderson, J. E., Kopecky, K. J., Willman, C. L., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0354 · Cited by 192 · see citing works

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

Alessandrino, E. P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L. N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., et al. (2002) · PubMed · Cited by 178 · see citing works

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

Gardin, C., Turlure, P., Fagot, T., Thomas, X., Terré, C., Contentin, N., Raffoux, E., de Botton, S., Pautas, C., Reman, O., et al. (2007) · Blood · doi:10.1182/blood-2007-02-069666 · Cited by 174 · see citing works

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

Harousseau, J., Martinelli, G., Wiktor-Jędrzejczak, W., Brandwein, J. M., Bordessoule, D., Masszi, T., Ossenkoppele, G. J., Alexeeva, J. A., Beutel, G., Maertens, J. A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198093 · Cited by 149 · see citing works

Prognostic Impact of Acute Myeloid Leukemia Classification: Importance of Detection of Recurring Cytogenetic Abnormalities and Multilineage Dysplasia on Survival

Forman, S. J., Slovak, M. L., Arber, D. A., et al. (2003) · American Journal of Clinical Pathology · doi:10.1309/em7k-cqr4-glmh-rcx4 · Cited by 147 · see citing works

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

Estey, E. H., Thall, P. F., Giles, F. J., Wang, X., Cortes, J. E., Beran, M., Pierce, S. A., Thomas, D. A., & Kantarjian, H. M. (2002) · Blood · doi:10.1182/blood.v99.12.4343 · Cited by 138 · see citing works

Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.

Deschler-Baier, B., de Witte, T., Mertelsmann, R. H., & Lübbert, M. (2006) · PubMed · Cited by 138 · see citing works

Prognostic Impact of Acute Myeloid Leukemia Classification

Arber, D. A., Stein, A. S., Carter, N. H., et al. (2003) · American Journal of Clinical Pathology · doi:10.1309/em7kcqr4glmhrcx4 · Cited by 119 · see citing works

Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high‐risk karyotypes

Knipp, S., Hildebrand, B., Kündgen, A., Giagounidis, A. A. N., Kobbe, G., Haas, R. R., Aul, C., Gattermann, N., & Germing, U. (2007) · Cancer · doi:10.1002/cncr.22779 · Cited by 112 · see citing works

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

Fenaux, P., Raza, A., Mufti, G. J., Aul, C., Germing, U., Kantarjian, H. M., Cripe, L. D., Kerstens, R., Porre, P. D., & Kurzrock, R. (2007) · Blood · doi:10.1182/blood-2006-07-035725 · Cited by 104 · see citing works

Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia

Giles, F. J., Rizzieri, D. A., Karp, J. E., Vey, N., Ravandi, F., Faderl, S. H., Khan, K. D., Verhoef, G. E. G., Wijermans, P., Advani, A. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0961 · Cited by 84 · see citing works

A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

Hellström‐Lindberg, E., Robèrt, K., Gahrton, G., Lindberg, G., Forsblom, A., Kock, Y., & Öst, Å. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb02982.x · Cited by 76 · see citing works

Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.

Cheson, B. D., & Simon, R. M. (1987) · PubMed · Cited by 68 · see citing works

Classification of acute leukemias

Brunning, R. D. (2003) · Seminars in Diagnostic Pathology · doi:10.1016/s0740-2570(03)00031-5 · Cited by 60 · see citing works

Acute Myeloid Leukemia in the Elderly

Dombret, H., Raffoux, E., & Gardin, C. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.013 · Cited by 58 · see citing works

Treatment of acute myeloid leukemia

Estey, E. H. (2008) · Haematologica · doi:10.3324/haematol.2008.001263 · Cited by 56 · see citing works

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.

Bernstein, S. H., Brunetto, V. L., Davey, F. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2486 · Cited by 56 · see citing works

Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals

Strupp, C., Gattermann, N., Giagounidis, A. A. N., et al. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00220-5 · Cited by 43 · see citing works

Acute myeloid leukemia in the elderly: Conventional and novel treatment approaches

Craig, C. M., & Schiller, G. J. (2008) · Blood Reviews · doi:10.1016/j.blre.2008.03.002 · Cited by 40 · see citing works

A Phase II Study (Biov-121) of Clofarabine Monotherapy First Line in Patients Aged 65 Years or Older with Acute Myeloid Leukemia for Whom Standard Intensive Chemotherapy Is Not Considered Suitable.

Burnett, A. K., Baccarani, M., Johnson, P. R. E., et al. (2006) · Blood · doi:10.1182/blood.v108.11.425.425 · Cited by 34 · see citing works

Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia.

Jp, W., & Hl, H. (2000) · PubMed · Cited by 22 · see citing works

Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia

Albitar, M. X., Beran, M., O'Brien, S. M., et al. (2000) · Blood · doi:10.1182/blood.v96.1.372.013k56c_372_374 · Cited by 21 · see citing works

Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Erba, H. P., Kantarjian, H. M., Claxton, D. F., et al. (2008) · Blood · doi:10.1182/blood.v112.11.558.558 · Cited by 17 · see citing works

Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia

Albitar, M. X., Beran, M., O'Brien, S. M., et al. (2000) · Blood · doi:10.1182/blood.v96.1.372 · Cited by 17 · see citing works

Effects of Initial Treatment on Survival among Elderly AML Patients: Findings from the SEER-Medicare Database.

Menzin, J., Boulanger, L., Karsten, V., et al. (2006) · Blood · doi:10.1182/blood.v108.11.1973.1973 · Cited by 16 · see citing works

Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?

Detourmignies, L., Wattel, E., Laı̈, J. L., Bauters, F., & Fenaux, P. (1993) · Annals of Hematology · doi:10.1007/bf01738471 · Cited by 16 · see citing works

ERRATUM

(1998) · Blood · doi:10.1182/blood.v91.3.1100 · Cited by 9 · see citing works

Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.

Fukuhara, T., Miyake, T., Maekawa, I., et al. (2000) · PubMed · Cited by 7 · see citing works

Acute Leukemia in Patients Sixty Years of Age and Older

Leger, C. S., Leitch, H. A., Galbraith, P. F., Li, C. H., & Vickars, L. M. (2009) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31818a6c93 · Cited by 4 · see citing works

Refractory Anaemia with Excess of Blasts in Transformation Re-Evaluated with the WHO Criteria: Identification of Subgroups with Different Survival

Breccia, M., Latagliata, R., Carmosino, I., et al. (2007) · Acta Haematologica · doi:10.1159/000098957 · Cited by 3 · see citing works

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900 · see citing works

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825 · see citing works

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165 · see citing works

The roles of DNA, RNA and histone methylation in ageing and cancer

Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works

Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine

Liu, M., Ohtani, H., Zhou, W., Ørskov, A. D., Charlet, J., Zhang, Y. W., Shen, H., Baylin, S. B., Liang, G., Grønbæk, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612262113 · Cited by 225 · see citing works

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

de Botton, S., Mondesir, J., Willekens, C., & Touat, M. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s70716 · Cited by 220 · see citing works

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Raffoux, E., Cras, A., Recher, C., Boëlle, P.-Y., de Labarthe, A., Turlure, P., Marolleau, J.-P., Reman, O., Gardin, C., Victor, M., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.106 · Cited by 134 · see citing works

Current status and new treatment approaches in TP53 mutated AML

Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102 · see citing works

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

Fehniger, T. A., Uy, G. L., Trinkaus, K., Nelson, A. D., Demland, J., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., Westervelt, P., DiPersio, J. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-297143 · Cited by 107 · see citing works

Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States

Zeidan, A. M., Wang, R., Wang, X., Shallis, R. M., Podoltsev, N. A., Bewersdorf, J. P., Huntington, S. F., Neparidze, N., Giri, S., Gore, S. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001779 · Cited by 93 · see citing works

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-680546 · Cited by 93 · see citing works

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Craddock, C. F., Houlton, A. E., Quek, L. S., Ferguson, P., Gbandi, E., Roberts, C., Metzner, M., Garcia-Martin, N., Kennedy, A., Hamblin, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1423 · Cited by 88 · see citing works

Digging deep into “dirty” drugs – modulation of the methylation machinery

Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84 · see citing works

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605

Sekeres, M. A., Gundacker, H., Lancet, J., Advani, A., Petersdorf, S., Liesveld, J., Mulford, D., Norwood, T., Willman, C. L., Appelbaum, F. R., et al. (2011) · Blood · doi:10.1182/blood-2011-02-337303 · Cited by 80 · see citing works

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models

Fang, D. D., Tang, Q., Kong, Y., Rong, T., Wang, Q., Li, N., Fang, X., Gu, J., Xiong, D., Yin, Y., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00465-5 · Cited by 58 · see citing works

Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia

Szmigielska‐Kapłon, A., & Robak, T. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798940 · Cited by 19 · see citing works

Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions

Short, N. J., & Kantarjian, H. M. (2022) · American Journal of Hematology · doi:10.1002/ajh.26667 · Cited by 37 · see citing works

P-301 Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Freyrie, A., Reda, G., Vincenti, D., et al. (2013) · Leukemia Research · doi:10.1016/s0145-2126(13)70348-5

168 Impact of comorbidities in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) treated with azacitidine (AZA)

Font, P. A., de Soria, V. G.-G., Callejas, M. E. R., et al. (2011) · Leukemia Research · doi:10.1016/s0145-2126(11)70170-9

MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia

Krejčík, Z., Beličková, M., Hruštincová, A., Votavová, H., Jonasova, A. T., Čermák, J., Dyr, J. E., & Merkerová, M. D. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171029 · Cited by 22 · see citing works